Cameron Santoro

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old.

The 2023 coverage of the annual meeting of the American Academy of Dermatology (AAD) included FDA approvals, new treatment methods, patient advocacy, and more.

A collection of studies was used to analyze the strongest strategies in acute-care settings for patients with substance use disorders.

Hidradenitis suppurativa can either worsen or benefit depending on various dietary influences, either included, or excluded by the patient.

Shiela Plasencia, director of practice support, Community Oncology Alliance (COA), discusses health equity initiatives and the challenges that follow.

Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.

Utilizing artificial intelligence (AI) to diagnose skin cancer raises concerns around the level of accuracy it delivers consumers, health care professionals, and other dermatology experts.

Patients with vitiligo can increase repigmentation through vitamin D and topical corticosteroid therapy.

Electronic nicotine devices, originally marketed to help smokers quit cigarettes, have resulted in a worldwide outbreak of adolescent nicotine consumers.

Despite common assumptions, smoking prevalence in individuals relies on sociodemographic disparities rather than health disparities.